MetaVia is trading 5.97% higher at $1.62, extending its August 24 close of $1.53; no new company-specific announcement or clearly reported catalyst was identified for August 25, 2026.
- The latest major corporate update remains the August 6 second-quarter report, which highlighted DA-1726 clinical progress.
- Broader markets are modestly higher, but available evidence does not establish that macro sentiment directly caused MetaVia’s move.